/
HCWB
$0.88-$0.92 (-14.95%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.4M
7M shares
52-week range
$1.50 – $44.10
-1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
599.43%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1506.74
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $4.1M | $0 | $6.7M | $2.8M | $2.6M | $54.2K |
| Cost of revenue | $421.8K | $0 | $0 | $4.1M | $2.3M | $1.6M | $43.4K |
| Gross profit | −$421.8K | $4.1M | $0 | $2.6M | $560.4K | $959.4K | $10.8K |
| Gross margin | — | 100.0% | — | 38.5% | 19.7% | 37.4% | 20.0% |
| R&D | $5.1M | $7.3M | $8.2M | $9.3M | $7.7M | $6.4M | $5.4M |
| Operating income | −$7.4M | −$5.8M | −$13.4M | −$15.1M | −$25.7M | −$29.5M | −$11.3M |
| EBITDA | −$6.9M | −$5.3M | −$12.3M | −$14.1M | −$23.6M | −$27.7M | −$5.7M |
| Net income | −$7.3M | −$5.8M | −$12.9M | −$14.9M | −$25.0M | −$30.0M | −$8.0M |
| Net margin | — | -141.0% | — | -221.7% | -879.5% | -1169.7% | -14677.1% |
| EPS (diluted) | -0.21 | -0.16 | -0.36 | -0.42 | -0.70 | -0.77 | -10.63 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-0.48 | $-0.48–$-0.48 | 1 |
| 2027 | $34M | $-0.44 | $-0.44–$-0.44 | 1 |
| 2028 | $46M | $-0.35 | $-0.35–$-0.35 | 1 |
| 2029 | $6429 | $-0.30 | $-0.30–$-0.30 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
HCW Biologics Inc. Common Stock
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
www.hcwbiologics.com- Employees
- 35
- IPO / List date
- Jul 20, 2021
- HQ
- MIRAMAR, FL
Held by traders on TradeandTell
No one on the platform currently holds HCWB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in HCWB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-30 | 1-for-6reverse |
| 2025-04-11 | 1-for-40reverse |
Recent trades on TradeandTell
No one on the platform has traded HCWB yet.
